a non-psychoactive cannabinoid from hemp


THCv is a relatively new cannabinoid on the market not considered to be psychoactive. Thanks largely to prohibition this cannabinoid has not been as well studied and research is limited. Despite this current lack of research, in the last decade studies have come out revealing the potential for therapeutic treatment utilizing THCv.

THCv is the cannabinoid responsible for the ”get up and go” feeling of strong Sativa’s. It is suggested this may be in part due to the THCv’s ability to blunt the well known effects of THC including paranoia and anxiety (Englund et al. 2015).

THCv is also thought to be of particular interest in the treatment of the symptoms of type 2 diabetes as THCv has been demonstrated to improve insulin resistance, decrease fasting plasma glucose and improve pancreatic function in humans. (Muniyappa et al. 2013) (Jadoon et al. 2016)

THCv is an interesting cannabinoid with great potential, at least one researcher remarked ”THCv may provide a template for the development of new therapeutics for type 2 diabetes.” (Jadoon et al. 2016)


One thing we see from CBD companies that we would never do, is to use a study to promote their products without acknowledging the dosage. If you’re looking to get the benefits of THCv, at least one human study used an oral dose of 10mg (Englund et al. 2015). Unlike other companies, The Highest Ground Coffee Company offers and infused THCv coffee with ~8mg per cup and is backed by laboratory testing, matching the study dosage. We’ve extensively tested our Energetic Jane formulation to help us target an effective dose of THCv and CBD in every cup. Are you ready to try THCv infused coffee?

Interested in Learning More?

Sign up to get notified about our educational content, promotions and more.

Supporting Research

McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737–53.

Tudge L, Williams C, Cowen PJ, McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol. 2015;18(6):1–9.

Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan M, Di Marzo V, Cawthorne MA. The cannabinoid D(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3(5):e68.

Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M, Courville A, Hall G, Chen KY, Volkow ND, Kunos G. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013;36(8):2415–22.

Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O’Sullivan SE, Tan GD. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777–86.

Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five-day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol. 2015;30(2):140–51.

Abioye, A., Ayodele, O., Marinkovic, A. et al. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. J Cannabis Res 2, 6 (2020).